Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis

Downregulation of Plk1 Expression By Receptor-Mediated Uptake of Antisense Oligonucleotide-Loaded Nanoparticles

(2015) Birgit Spänkuch et al.   NEOPLASIA

Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape

(2011) René Bartz et al.   BIOCHEMICAL JOURNAL

Targeting Polo-like Kinase in Cancer Therapy

(2010) Y. Degenhardt et al.   CLINICAL CANCER RESEARCH

Future Prospect of RNA Interference for Cancer Therapies

(2010) Eishi Ashihara et al.   CURRENT DRUG TARGETS

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

siRNA delivery systems for cancer treatment

(2009) Yu-Kyoung Oh et al.   ADVANCED DRUG DELIVERY REVIEWS

Concepts in in vivo siRNA delivery for cancer therapy

(2009) Christopher S. Gondi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

(2009) Adam D. Judge et al.   JOURNAL OF CLINICAL INVESTIGATION

Assessment of siRNA pharmacokinetics using ELISA-based quantification

(2009) Eun-Joong Kim et al.   JOURNAL OF CONTROLLED RELEASE

Evolving novel anti-HER2 strategies

(2009) Kellie L Jones et al.   LANCET ONCOLOGY

Structural basis for RNA-silencing suppression by Tomato aspermy virus protein 2b

(2008) Hong-Ying Chen et al.   EMBO REPORTS

Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes

(2008) D AUGUSTE et al.   JOURNAL OF CONTROLLED RELEASE

Nonviral Methods for siRNA Delivery

(2008) Kun Gao et al.   MOLECULAR PHARMACEUTICS